Published: September 2014, Bio Medical Research International https://cellpointweb.com/wp-content/uploads/2019/11/Patched-Targeting-Peptides-for-Imaging-and-Treatment-of-Hedgehog-Postive-Breast-Tumors.pdf
Read MoreCENTENNIAL, Colo., April 9, 2013—Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled Ethylenedicysteine-Glucosamine (99mTc-EC-G), Cell>Point’s proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of schemia in patients with Coronary…
Read MoreThird License Completes the Company’s Initiative to Secure a Strong Pharmaceutical Partner for the South Korean Market CENTENNIAL, Colo., March 11, 2013—Cell>Point announced today that it entered into a license agreement on December 17,2012 with Hanmi Pharmaceutical Co., Ltd (Hanmi) who is headquartered in Seoul, Korea. The license agreement also includes HYUN IMC as a party (who Cell>Point previously…
Read MorePublished: January 2013, Vol. 20, No. 1, Academic Radiology https://cellpointweb.com/wp-content/uploads/2019/11/Deveopment-of-99mTc-EC-tyrosine-for-Early-Detection-of-Breast-Cancer-Tumror-Response-to-the-Anticancer-Drug-Melphalan.pdf
Read MoreCENTENNIAL, Colo., September 11, 2012 – Cell>Point announced today that Cardiovascular Imaging Technologies presented a Phase 1b clinical trial abstract for its cardiology imaging agent, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glocosamine), used to image ischemic patients during rest and exercise stress testing at the American Society of Nuclear Cardiology 2012 Meeting on September 6, 2012. https://www.cellpointweb.com/pdf/press/CellPoint-Press-Release-Sept-11-2012.pdf See the Myocardial Uptake of…
Read MoreCENTENNIAL, Colo., March 17, 2012 – Cell>Point today that Company President David Rollo, M.D., Ph.D.,will present at the 26th Indian Oncology Network (ICON) Meeting in Bengaluru, India, On Saturday, March 27, 2012, at 10:45 a.m. local time. The ICON meeting will be held at the Crowne Plaza in Bengaluru.
Read MoreCENTENNIAL, Colo., March 8, 2012 – Cell>Point, L.L.C , announced today that it received a letter from the U.S. Food and Drug Administration (FDA) indicating that agreement has been reached pursuant to a Special Protocol Assessment regarding the design of its Phase 3 pivotal clinical study in lung cancer.
Read MoreCENTENNIAL, Colo., February 28, 2012 – Cell>Point announced today that it had entered into a licensing agreement for countries of the South Korea, Taiwan, Malaysia, Vietnam, and the Philippines with HYUN IMC Co.,Ltd., headquatered in Seoul, South Korea.
Read MoreCell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.” The agreement leads with Cell>Point’s cancer and cardiology molecular imaging agent—EC-G or, specifically, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine)—but covers the entire portfolio of products being developed by Cell>Point. EC-G has completed a…
Read MoreCell>Point announced today that the University of Texas M.D. Anderson Cancer Center will present pre-clinical results on Cell>Point’s therapeutic, Platinum-EC-G, for Aggressive type-B Lymphoma at the 53rd American Society of Hematology Annual Meeting December 10-13, 2011
Read More